This is the authors' abstract. We don't add key points for this paper.
Cordycepin, a natural compound extracted from the fungus Cordyceps militaris, is a 3-deoxyadenosine and a key active ingredient in traditional Chinese medicine exhibiting promising anticancer properties. However, due to its poor bioavailability and short half-life, the usage of Cordycepin is limited clinically. To overcome these limitations, a liposome-based nanoformulation of cordycepin (CorLNP) is developed using thin-film hydration method. The physio-chemical properties of CorLNP revealed that, the particles are spherical in shape, the presence of functional groups is -OH and C = C groups, and these are playing major role in the formation CorLNP and maintaining the stability of the CorLNP. The entrapment efficiency of CorLNP 72% and drug loading capacity was 3.4%. The in vitro cytotoxicity and the apoptosis effect of the Cordycepin loaded liposome-based nano particles (CorLNP) and Cordycepin alone were assessed in human breast and cervical cancer cell lines. The CorLNP exhibited better cytotoxicity with greater fold-change both in MCF-7 and HeLa cell lines in a time dependant manner. These findings highlighted the incorporation of cordycepin into liposomal nanoparticles enhanced the bioavailability of cordycepin and significantly improved its anticancer efficacy.
No takes yet. Share an insight, caveat, or question.
Sridhar et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: